Lakewood-Amedex Biotherapeutics (LABT) closed at $0.31 on October 23, 2026, down 36.6% from the previous close, on volume of 4,255,426 shares (30-day average 1,669,627).
Data as of October 23, 2026.
PRNewswire (Wed, 21-Oct 8:03 AM ET)
PRNewswire (Wed, 7-Oct 8:05 AM ET)
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
PRNewswire (Thu, 1-Oct 8:02 AM ET)
PRNewswire (Mon, 28-Sep 8:02 AM ET)
PRNewswire (Thu, 24-Sep 8:02 AM ET)
PRNewswire (Mon, 21-Sep 8:02 AM ET)
PRNewswire (Fri, 18-Sep 8:15 AM ET)
PRNewswire (Tue, 8-Sep 8:02 AM ET)
LABT’s Nu-3 Demonstrates High Barrier to Resistance in Addressing Antibiotic-Resistant Bacteria
Market Chameleon (Wed, 22-Jul 5:52 AM ET)
Market Chameleon (Wed, 22-Jul 4:34 AM ET)
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Lakewood-Amedex Biotherapeutics trades on the NASDAQ stock market under the symbol LABT.
As of October 23, 2026, LABT stock price declined to $0.31 with 4,255,426 million shares trading.
LABT has a beta of -0.92, meaning it tends to be less sensitive to market movements. LABT has a correlation of 0.00 to the broad based SPY ETF.
LABT has a market cap of $734,603.00. This is considered a Sub-Micro Cap stock.
LABT support price is $.44 and resistance is $.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LABT shares will trade within this expected range on the day.
